Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319254 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00319254 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 75 participants.
The verdict
NCT00319254, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.
Interventions
- DRUG SKI-606 (Bosutinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00319254
The ClinicalTrials.gov registry entry for NCT00319254 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SKI-606 (Bosutinib) is the first listed.
NCT00319254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00319254 about?
NCT00319254 is a clinical study titled "Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer". The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.
What is the current status of trial NCT00319254?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2006-05. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00319254?
The interventions under investigation include: SKI-606 (Bosutinib) (DRUG).
Who is sponsoring clinical trial NCT00319254?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.